Ribociclib plus Endocrine Therapy in Early Breast Cancer

J. Slamon, Dennis; Lipatov, Oleg; Nowecki, Zbigniew; P. McAndrew, Nicholas; Kukiełka-Budny, Bożena; Stroyakovskiy, Daniil; A. Yardley, Denise; Huang, Chiun‐Sheng; A. Fasching, Peter; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock‐Ah; Ruíz-Borrego, Manuel; Loi, Sherene; Xu, Binghe; A. Hurvitz, Sara; H. Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, F.; Afenjar, Karen; Fresco, Rodrigo; Severin, Irene; Ji, Yan; Ghaznawi, Farhat; Li, Zheng; Pablo Zarate, Juan; Chakravartty, Arunava; Taran, Tetiana; N. Hortobágyi, Gabriel

doi:10.1056/nejmoa2305488

Public

Ribociclib plus Endocrine Therapy in Early Breast Cancer

Published in New England Journal of Medicine • Mar 20, 2024

Authors:

Dennis J. Slamon

Oleg Lipatov

Zbigniew Nowecki

Abstract

BACKGROUND: Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether this benefit in advanced breast cancer extends to early breast cancer is uncl...

Subject

Medicine

Letrozole

Breast cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!